Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Synergic pharmaceutical composition treating tumors

A composition and drug technology, applied in the direction of drug combination, antineoplastic drugs, heterocyclic compound active ingredients, etc., can solve the problems of autophagy inhibitors and beta interferon tumors that have not been seen yet

Inactive Publication Date: 2014-08-20
FUDAN UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] So far, there have been no reports on the combined administration or sequential administration of autophagy inhibitors and interferon-beta made into compound drugs or compositions to treat tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synergic pharmaceutical composition treating tumors
  • Synergic pharmaceutical composition treating tumors
  • Synergic pharmaceutical composition treating tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1: Preparation of beta interferon and autophagy inhibitory drugs

[0030] Preparation of beta interferon drug: Weigh 0.25 mg of recombinant human interferon β-1b, dissolve it in 1 ml of 0.54% sterile sodium chloride solution, stir thoroughly for 30 minutes and filter it with a 0.1 μm sterile filter, and divide it into 10 tubes for storage, each with 100 μl. The activity of interferon beta is 8.0MIU / ml;

[0031] Formulating autophagy-inhibiting drugs:

[0032] (1) Preparation of chloroquine: Dissolve an appropriate amount of chloroquine in pure water to make a 10mmol / L storage solution, filter and sterilize it with a 0.1μm filter, store it at 4°C, and dilute it 500-1000 times in an in vitro laboratory to inhibit cell autogenesis. bite;

[0033](2) Preparation of ammonium chloride: Dissolve an appropriate amount of ammonium chloride in water to make a 0.4mol / L storage solution, filter and sterilize with a 0.1μm filter, and store at 4°C. In vitro experimen...

Embodiment 2

[0039] Example 2: Interferon-beta can cause the formation of autophagosomes in human glioma cells

[0040] Human glioma cells U251MG and U87MG cells were treated with 2000IU / ml interferon-beta for 48 hours respectively, the cells were collected and fixed, and samples were prepared for electron microscopy. showed that the enlarged electron micrographs can clearly observe the autophagosome structure with double-layer to multi-layer membranes (such as figure 1 shown).

Embodiment 3

[0041] Example 3: Interferon-beta can induce autophagy signal generation in human glioma cells

[0042] Human glioma U251MG and U87MG cells were treated with 2000IU / ml β-interferon for 48 hours, and the cells treated with 500nM rapamycin for 12 hours were used as positive controls. After the dye was stained, it was observed with a laser confocal microscope. As a result, the negative control had no autophagy-related green fluorescence, and the positive controls treated with interferon-beta and rapamycin had autophagy-related green fluorescence (such as figure 2 shown).

[0043]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines and biology, relates to a synergic pharmaceutical composition treating tumors, and especially relates to a compound medicine or a pharmaceutical composition prepared from one or a plurality of cell autophagy inhibitors and beta interferon. The cell autophagy inhibitor(s) and beta interferon of the synergic pharmaceutical composition are administrated in a combined administration manner or in a sequential administration manner. By inhibiting autophagy of tumor cells induced by beta interferon, the antagonistic action, caused by cell autophagy, of tumor on treatment of beta interferon is offset, and therefore the killing effect of individually-used beta interferon on tumors is enhanced, and the treatment effect of beta interferon on tumors is substantially enhanced. The synergic medicine is applicable to glioma, pancreas cancer, lung cancer, liver tumor, vascular cancer and myeloma, and the treatment effect of individually-used beta interferon on tumors is substantially enhanced.

Description

technical field [0001] The invention belongs to the fields of medicine and biotechnology, and relates to antitumor drugs, in particular to a synergistic pharmaceutical composition for treating tumors, especially to a compound drug or compound drug made of one or more cell autophagy inhibitors and beta interferon The pharmaceutical composition, the synergistic pharmaceutical composition can be used for treating glioma, pancreatic cancer, lung cancer, liver tumor, vascular cancer and myeloma through combined administration or sequential use. Background technique [0002] Malignant glioma is the most common malignant tumor in the central nervous system with the highest incidence rate, accounting for about 30% of adult brain tumors. In the past 30 years, various treatment methods such as surgery, radiotherapy and chemotherapy have been improved, and have played a certain role in the treatment of glioma, but the survival rate of patients has not increased significantly. Practic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K38/21A61P35/00A61K31/585A61K31/45A61K31/365A61K33/20A61K31/4706A61K31/5377
Inventor 鞠佃文李玉彬钱晓璐曾贤范佳君王子玉王绍飞
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com